3/25/2014 8:32:33 AM
WOBURN, Mass.--(BUSINESS WIRE)--Courtagen Life Sciences announced today an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders. Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
Help employers find you! Check out all the jobs and post your resume.
comments powered by